Patient-reported outcomes (PROs) provide insight into patients’ experiences related to their illness, values, preferences, and goals of care and may therefore be useful as predictors of increased risk of mortality in patients with systemic lupus erythematosus (SLE). Due to their ease of use, PROs can be measured easily, quickly, and reliably, especially in communities where access to rheumatologists may be limited. As patients, and their families, prefer to be engaged in their care, it is imperative that clinicians focus on including personalized decision-making, educating patients about their disease and treatment options, and updating them on the progress of their care. However, there continue to be barriers to shared decision-making (SDM) in SLE, including medication risk aversion, prognosis uncertainty, and the financial and administration burdens associated with SLE care.
The final episode in this CMEOCast podcast series on SLE addresses the impact and burden of SLE on quality of life, the integration of PROs when caring for patients with SLE, and the implementation of best practices for SDM in order to engage patients as partners in their care.
At the end of this CME/CE activity, participants should be able to: incorporate SDM into the selection of safe and effective SLE treatments to improve disease outcomes.
The following learning objectives pertain only to those requesting CNE or CPE credit: Describe ways SDM can be incorporated into the selection of safe and effective SLE treatments to improve disease outcomes.
Supported by an educational grant from AstraZeneca Pharmaceuticals.
Rheumatologists, dermatologists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gibofsky reports that he is on the advisory committee for AbbVie Inc.; Aurinia Pharmaceuticals Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a consultant for AbbVie Inc.; Acquist Therapeutics, Inc.; Amgen Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a stock shareholder (directly purchased) for AbbVie Inc.; Johnson & Johnson; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.
Dr. Furie reports that he receives research support from Amgen Inc.; AstraZeneca/Medimmune; Biogen Idec; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc./Roche; GlaxoSmithKline; Kezar Life Sciences, Inc.; Nektar Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is a consultant for Alexion Pharmaceuticals, Inc.; AstraZeneca/Medimmune; Biogen Idec; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eli Lilly and Company; EMD Serono, Inc.; Equillium, Inc.; Galapagos; Genentech, Inc./Roche; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Kezar Life Sciences, Inc.; MorphoSys US Inc.; Novartis; Reistone Biopharma; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is an investigator for Amgen Inc.; AstraZeneca/Medimmune; Biogen Idec; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Eli Lilly and Company; EMD Serono, Inc.; Equillium, Inc.; Genentech, Inc./Roche; GlaxoSmithKline; Kezar Life Sciences, Inc.; Nektar Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is a committee member for the Lupus Research Alliance and The Lupus Academy.
Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-095-H01-P
Call us at (877) CME-PROS or (877) 263-7767.